Cargando...
Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status
The efficacy of standard antidepressants is limited for many patients with mood disorders such as major depressive disorder (MDD) and bipolar depression, underscoring the urgent need to develop novel therapeutics. Both clinical and preclinical studies have implicated glutamatergic system dysfunction...
Guardado en:
| Publicado en: | CNS Drugs |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2021
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8201267/ https://ncbi.nlm.nih.gov/pubmed/33904154 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40263-021-00816-x |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|